Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: A longitudinal study

Cancer Immunology, Immunotherapy

Volumn 58, Issue 1, 2009, Pages 111-120

  Mozaffari, Fariba ^a   Lindemalm, Christina ^a   Choudhury, Aniruddha ^a   Granstam Björneklett, Helena ^b   Lekander, Mats ^c   Nilsson, Bo ^a   Ojutkangas, Marja Leena ^d   Österborg, Anders ^a   Bergkvist, Leif ^b,d   Mellstedt, Håkan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Chemotherapy; NK cells; Radiation; T cells

Indexed keywords

CD28 ANTIGEN; CELL PROTEIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; PHOSPHATIDYLINOSITOL 3 KINASE; PHYTOHEMAGGLUTININ; PROTEIN KINASE ZAP 70; PROTEIN P56; PROTEIN P59; T LYMPHOCYTE RECEPTOR; TUBERCULIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FLOW CYTOMETRY; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LONGITUDINAL STUDIES; MIDDLE AGED; REFERENCE STANDARDS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES;

EID: 54849422416     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-008-0530-5     Document Type: Article

References (38)

1. L Arnould M Gelly F Penault-Llorca L Benoit F Bonnetain C Migeon V Cabaret V Fermeaux P Bertheau J Garnier JF Jeannin B Coudert 2006 Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94 259 267
2. W Asavaroengchai Y Kotera JJ Mule 2002 Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery Proc Natl Acad Sci USA 99 931 936
3. E Baral E Nagy I Berczi 1995 Modulation of natural killer cell-mediated cytotoxicity by tamoxifen and estradiol Cancer 75 591 599
4. +CD28 regulatory cells in suppressing myasthenia gravis-associated responses by a dual altered peptide ligand Proc Natl Acad Sci USA 104 17459 17464
5. WE Carson R Parihar MJ Lindemann N Personeni J Dierksheide NJ Meropol J Baselga MA Caligiuri 2001 Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells Eur J Immunol 31 3016 3025
6. A Cheda EM Nowosielska J Wrembel-Wargocka MK Janiak 2008 Production of cytokines by peritoneal macrophages and splenocytes after exposures of mice to low doses of X-rays Radiat Environ Biophys 47 2 275 283
7. F Cheng D Gabrilovich EM Sotomayor 2004 Immune tolerance in breast cancer Breast Dis 20 93 103
8. RA Clynes TL Towers LG Presta JV Ravetch 2000 Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Nat Med 6 443 446
9. ML Disis TA Gooley K Rinn D Davis M Piepkorn MA Cheever KL Knutson K Schiffman 2002 Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines J Clin Oncol 20 2624 2632
10. A Fattorossi A Battaglia G Ferrandina F Coronetta F Legge V Salutari G Scambia 2004 Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma Cancer 100 1418 1428
11. G Filaci D Fenoglio M Fravega G Ansaldo G Borgonovo P Traverso B Villaggio A Ferrera A Kunkl M Rizzi F Ferrera P Balestra M Ghio P Contini M Setti D Olive B Azzarone G Carmignani JL Ravetti G Torre F Indiveri 2007 CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers J Immunol 179 4323 4334
12. R Gennari S Menard F Fagnoni L Ponchio M Scelsi E Tagliabue F Castiglioni L Villani C Magalotti N Gibelli B Oliviero B Ballardini G Da Prada A Zambelli A Costa 2004 Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 Clin Cancer Res 10 5650 5655
13. F Ghiringhelli C Menard PE Puig S Ladoire S Roux F Martin E Solary A Le Cesne L Zitvogel B Chauffert 2007 Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients Cancer Immunol Immunother 56 641 648
14. AM Gonzalez-Angulo GN Hortobagyi FJ Esteva 2006 Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer Oncologist 11 857 867
15. C Hellman K Lonnkvist G Hedlin G Hallden J Lundahl 2002 Down-regulated IL-5 receptor expression on peripheral blood eosinophils from budesonide-treated children with asthma Allergy 57 323 328
16. AL Hjelm Skog M Wadhwa M Hassan B Gharizadeh C Bird P Ragnhammar R Thorpe H Mellstedt 2001 Alteration of interleukin 2 (IL-2) pharmacokinetics and function by IL-2 antibodies induced after treatment of colorectal carcinoma patients with a combination of monoclonal antibody 17-1A, granulocyte macrophage colony-stimulating factor, and IL-2 Clin Cancer Res 7 1163 1170
17. JN Kochenderfer JL Simpson CD Chien RE Gress 2007 Vaccination regimens incorporating CpG-containing oligodeoxynucleotides and IL-2 generate antigen-specific anti-tumor immunity from T cell populations undergoing homeostatic peripheral expansion after BMT Blood 110 1 450 460
18. RA Kurt WJ Urba JW Smith DD Schoof 1998 Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules Int J Cancer 78 16 20
19. I Kuss AD Donnenberg W Gooding TL Whiteside 2003 Effector CD8+CD45RO-CD27-T cells have signalling defects in patients with squamous cell carcinoma of the head and neck Br J Cancer 88 223 230
20. JY Liu Y Wu XS Zhang JL Yang HL Li YQ Mao Y Wang X Cheng YQ Li JC Xia M Masucci YX Zeng 2007 Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine Cancer Immunol Immunother 56 1597 1604
21. J Lukac Z Kusic D Kordic M Koncar A Bolanca 1994 Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen Breast Cancer Res Treat 29 279 285
22. F Mozaffari L Hansson S Kiaii X Ju ED Rossmann H Rabbani H Mellstedt A Osterborg 2004 Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage Br J Haematol 124 315 324
23. F Mozaffari C Lindemalm A Choudhury H Granstam-Bjorneklett I Helander M Lekander E Mikaelsson B Nilsson ML Ojutkangas A Osterborg L Bergkvist H Mellstedt 2007 NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy Br J Cancer 97 105 111
24. EF Murta JM de Andrade RP Falcao S Bighetti 2000 Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy Tumori 86 403 407
25. R Nahta FJ Esteva 2006 HER2 therapy: molecular mechanisms of trastuzumab resistance Breast Cancer Res 8 215
26. M Orditura C Romano F De Vita G Galizia E Lieto S Infusino G De Cataldis G Catalano 2000 Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival Cancer Immunol Immunother 49 530 536
27. E Proietti G Greco B Garrone S Baccarini C Mauri M Venditti D Carlei F Belardelli 1998 Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice J Clin Invest 101 429 441
28. T Repka EG Chiorean J Gay KE Herwig VK Kohl D Yee JS Miller 2003 Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study Clin Cancer Res 9 2440 2446
29. E Robinson D Rubin T Mekori R Segal S Pollack 1993 In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer Cancer Immunol Immunother 37 209 212
30. G Schiavoni F Mattei T Di Pucchio SM Santini L Bracci F Belardelli E Proietti 2000 Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer Blood 95 2024 2030
31. YX Shan SZ Jin XD Liu Y Liu SZ Liu 2007 Ionizing radiation stimulates secretion of pro-inflammatory cytokines: dose-response relationship, mechanisms and implications Radiat Environ Biophys 46 21 29
32. I Smith M Procter RD Gelber S Guillaume A Feyereislova M Dowsett A Goldhirsch M Untch G Mariani J Baselga M Kaufmann D Cameron R Bell J Bergh R Coleman A Wardley N Harbeck RI Lopez P Mallmann K Gelmon N Wilcken E Wist P Sanchez Rovira MJ Piccart-Gebhart 2007 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 29 36
33. EF Solomayer M Feuerer L Bai V Umansky P Beckhove GC Meyberg G Bastert V Schirrmacher IJ Diel 2003 Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer Clin Cancer Res 9 174 180
34. D Tripathy 2005 Targeted therapies in breast cancer Breast J 11 Suppl 1 S30 S35
35. G Valabrega F Montemurro M Aglietta 2007 Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Ann Oncol 18 977 984
36. J Wasserman H Blomgren S Rotstein B Petrini S Hammarstrom 1989 Immunosuppression in irradiated breast cancer patients: in vitro effect of cyclooxygenase inhibitors Bull N Y Acad Med 65 36 44
37. LM Weiner GP Adams 2000 New approaches to antibody therapy Oncogene 19 6144 6151
38. H Yi Y Rong Z Yankai L Wentao Z Hongxia W Jie C Rongyue L Taiming L Jingjing 2006 Improved efficacy of DNA vaccination against breast cancer by boosting with the repeat beta-hCG C-terminal peptide carried by mycobacterial heat-shock protein HSP65 Vaccine 24 2575 2584